Kaken Pharmaceutical (TYO:4521) revised its consolidated earnings forecast for the fiscal year ending March 31, raising net sales outlook to 94 billion yen due to an upfront payment from a licensing deal for its STAT6 inhibitor.
Net profit was slightly adjusted downward to 14 billion yen, reflecting expenses from a recent dermatology licensing agreement and the acquisition of Aadi Subsidiaries, according to its Tuesday bourse filing.
The revision follows deals disclosed in December 2024 and March 2025, including a collaboration with Alumis for ESK-001 in Japan and the completion of Aadi's acquisition.
Despite the adjustments, Kaken's projected earnings still show significant growth compared with the previous fiscal year, with net sales up 30.5% and operating profit more than doubling.
Shares of the company dropped over 5% in morning trade Wednesday.
Price (JPY): $4236.00, Change: $-230, Percent Change: -5.13%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.